-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
We Think Zylox-Tonbridge Medical Technology (HKG:2190) Can Afford To Drive Business Growth
We Think Zylox-Tonbridge Medical Technology (HKG:2190) Can Afford To Drive Business Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, although Amazon.com made losses for many years after listing, if you had bought and held the shares since 1999, you would have made a fortune. But the harsh reality is that very many loss making companies burn through all their cash and go bankrupt.
So should Zylox-Tonbridge Medical Technology (HKG:2190) shareholders be worried about its cash burn? In this report, we will consider the company's annual negative free cash flow, henceforth referring to it as the 'cash burn'. The first step is to compare its cash burn with its cash reserves, to give us its 'cash runway'.
View our latest analysis for Zylox-Tonbridge Medical Technology
How Long Is Zylox-Tonbridge Medical Technology's Cash Runway?
A company's cash runway is calculated by dividing its cash hoard by its cash burn. In December 2021, Zylox-Tonbridge Medical Technology had CN¥2.9b in cash, and was debt-free. Looking at the last year, the company burnt through CN¥206m. So it had a very long cash runway of many years from December 2021. While this is only one measure of its cash burn situation, it certainly gives us the impression that holders have nothing to worry about. Depicted below, you can see how its cash holdings have changed over time.
SEHK:2190 Debt to Equity History July 6th 2022How Well Is Zylox-Tonbridge Medical Technology Growing?
Zylox-Tonbridge Medical Technology boosted investment sharply in the last year, with cash burn ramping by 61%. But shareholders are no doubt taking some confidence from the rockstar revenue growth of 544% during that same year. On balance, we'd say the company is improving over time. While the past is always worth studying, it is the future that matters most of all. For that reason, it makes a lot of sense to take a look at our analyst forecasts for the company.
How Easily Can Zylox-Tonbridge Medical Technology Raise Cash?
We are certainly impressed with the progress Zylox-Tonbridge Medical Technology has made over the last year, but it is also worth considering how costly it would be if it wanted to raise more cash to fund faster growth. Issuing new shares, or taking on debt, are the most common ways for a listed company to raise more money for its business. Many companies end up issuing new shares to fund future growth. We can compare a company's cash burn to its market capitalisation to get a sense for how many new shares a company would have to issue to fund one year's operations.
Zylox-Tonbridge Medical Technology's cash burn of CN¥206m is about 5.9% of its CN¥3.5b market capitalisation. Given that is a rather small percentage, it would probably be really easy for the company to fund another year's growth by issuing some new shares to investors, or even by taking out a loan.
So, Should We Worry About Zylox-Tonbridge Medical Technology's Cash Burn?
As you can probably tell by now, we're not too worried about Zylox-Tonbridge Medical Technology's cash burn. For example, we think its revenue growth suggests that the company is on a good path. While its increasing cash burn wasn't great, the other factors mentioned in this article more than make up for weakness on that measure. After taking into account the various metrics mentioned in this report, we're pretty comfortable with how the company is spending its cash, as it seems on track to meet its needs over the medium term. Readers need to have a sound understanding of business risks before investing in a stock, and we've spotted 1 warning sign for Zylox-Tonbridge Medical Technology that potential shareholders should take into account before putting money into a stock.
Of course Zylox-Tonbridge Medical Technology may not be the best stock to buy. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks that insiders are buying.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
僅僅因為一家企業沒有賺到錢,並不意味着股票會下跌。例如,雖然亞馬遜上市後多年虧損,但如果你從1999年開始買入並持有股票,你就會發大財。但殘酷的現實是,許多虧損的公司燒光了所有的現金,破產了。
所以也應該這樣Zylox-Tonbridge醫療技術(HKG:2190)股東擔心其燒錢?在這份報告中,我們將考慮該公司的年度自由現金流為負,此後將其稱為“現金消耗”。第一步是將它的現金消耗與其現金儲備進行比較,給我們提供它的“現金跑道”。
查看我們對Zylox-Tonbridge醫療技術的最新分析
Zylox-Tonbridge醫療科技的現金跑道有多長?
一家公司的現金跑道是通過將其現金儲備除以現金消耗來計算的。2021年12月,Zylox-Tonbridge醫療科技擁有29億元人民幣現金,並且沒有債務。回顧去年,該公司燒掉了2.06億元人民幣。因此,從2021年12月開始,它有一條很長的現金跑道。雖然這只是其燒錢情況的一個衡量標準,但它肯定給我們的印象是,持有者沒有什麼可擔心的。如下所示,你可以看到它的現金持有量是如何隨着時間的推移而變化的。
聯交所:2190債轉股歷史2022年7月6日Zylox-Tonbridge醫療技術的發展情況如何?
Zylox-Tonbridge醫療技術公司去年大幅增加了投資,現金消耗增加了61%。但股東們無疑從同年544%的搖滾明星收入增長中獲得了一些信心。總的來説,我們會説該公司正在隨着時間的推移而不斷進步。雖然過去總是值得研究的,但最重要的是未來。因此,看看我們的分析師對該公司的預測是很有意義的。
Zylox-Tonbridge醫療技術公司籌集現金有多容易?
Zylox-Tonbridge醫療技術在過去一年中取得的進步給我們留下了深刻的印象,但也值得考慮的是,如果它想要籌集更多現金來支持更快的增長,成本會有多高。發行新股或承擔債務是上市公司為其業務籌集更多資金的最常見方式。許多公司最終發行新股,為未來的增長提供資金。我們可以將一家公司的現金消耗與其市值進行比較,以瞭解一家公司需要發行多少新股才能為一年的運營提供資金。
Zylox-Tonbridge醫療技術公司2.06億元的現金消耗約佔其35億元人民幣市值的5.9%。鑑於這只是一個相當小的比例,該公司很可能很容易通過向投資者發行一些新股,甚至通過貸款來為下一年的增長提供資金。
那麼,我們應該擔心Zylox-Tonbridge醫療技術公司的燒錢嗎?
正如你現在可能已經知道的那樣,我們並不太擔心Zylox-Tonbridge醫療技術公司的燒錢。例如,我們認為它的收入增長表明該公司正走在一條良好的道路上。雖然它不斷增加的現金消耗並不是很好,但本文提到的其他因素足以彌補這一指標的疲軟。在考慮了這份報告中提到的各種指標後,我們對該公司如何使用現金相當滿意,因為它似乎有望在中期內滿足其需求。讀者在投資股票之前需要對商業風險有一個良好的瞭解,我們已經發現Zylox-Tonbridge醫療技術公司的1個警告標誌潛在股東在將資金投入股票之前應該考慮到這一點。
當然了Zylox-Tonbridge醫療技術公司可能不是最值得購買的股票。所以你可能想看看這個免費擁有高股本回報率的公司的集合,或內部人士正在購買的這份股票清單。
對這篇文章有什麼反饋嗎?擔心內容嗎? 保持聯繫直接與我們聯繫。或者,也可以給編輯組發電子郵件,地址是implywallst.com。
本文由Simply Wall St.撰寫,具有概括性。我們僅使用不偏不倚的方法提供基於歷史數據和分析師預測的評論,我們的文章並不打算作為財務建議。它不構成買賣任何股票的建議,也沒有考慮你的目標或你的財務狀況。我們的目標是為您帶來由基本面數據驅動的長期重點分析。請注意,我們的分析可能不會將最新的對價格敏感的公司公告或定性材料考慮在內。Simply Wall St.對上述任何一隻股票都沒有持倉。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧